Cristina Veintimilla Yánez

Mrs. Cristina Veintimilla Yánez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
RPRosalía Palomino-Cabrera
Rosalía Palomino-Cabrera
FTFrancisco Tejerina
Francisco Tejerina
AMAndrea Molero-Salinas
Andrea Molero-Salinas
MFMaría Ferris
María Ferris
CYCristina Veintimilla Yánez
Cristina Veintimilla Yánez
SVSofía de la Villa
Sofía de la Villa
The emergence of the Omicron variant of SARS-CoV-2 represented a challenge to the treatment of COVID-19 using monoclonal antibodies. Only Sotrovimab maintained partial activity, allowing it to be used in high-risk patients infected with the Omicron variant.

31 March 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
Maricela ValerioMaricela Valerio
Maricela Valerio
CYCristina Veintimilla Yánez
Cristina Veintimilla Yánez
CRCarmen Rodríguez
Carmen Rodríguez
SVSofía De la Villa
Sofía De la Villa
MSMar Sánchez-Somolinos
Mar Sánchez-Somolinos
PMPatricia Munoz
Patricia Munoz
Dalbavancin is an antibiotic with activity against gram-positive bacteria that allows early discharge of patients requiring intravenous therapy. Outpatient treatment helps offset hospitalisation co...

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
SBSergio Buenestado-Serrano
Sergio Buenestado-Serrano
MHMarta Herranz
Marta Herranz
RPRosalía Palomino-Cabrera
Rosalía Palomino-Cabrera
CRCristina Rodríguez-Grande
Cristina Rodríguez-Grande
DPDaniel Peñas-Utrilla
Daniel Peñas-Utrilla
DGDarío García-de-Viedma
Darío García-de-Viedma
Nanopore sequencing of multiple amplicons harboring signature single nucleotide polymorphisms (SNPs) escapes the targeting limitations of strain-specific PCRs and offers a powerful alternative to systematic whole-genome analysis, paving the way to real-time genomic epidemiology and making immediate intervention possible to finally optimize transmission control.

27 December 2023 in Journal of Medical Virology
Verified
Journal Article
Closed access
RPRosalía Palomino‐Cabrera
Rosalía Palomino‐Cabrera
FTFrancisco Tejerina
Francisco Tejerina
AMAndrea Molero‐Salinas
Andrea Molero‐Salinas
CYCristina Veintimilla Yánez
Cristina Veintimilla Yánez
PCPilar Catalán
Pilar Catalán
TGthe Gregorio Marañón Microbiology‐ID COVID 19 Study Group
the Gregorio Marañón Microbiology‐ID COVID 19 Study Group

23 January 2023 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
CYCristina Veintimilla Yánez
Cristina Veintimilla Yánez
PBPablo Bachiller-Luque
Pablo Bachiller-Luque
MCMaría Cornide-Santos
María Cornide-Santos
SHSusana Hernando-Real
Susana Hernando-Real

3 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRosalía Palomino-Cabrera
Rosalía Palomino-Cabrera
FTFrancisco Tejerina
Francisco Tejerina
AMAndrea Molero-Salinas
Andrea Molero-Salinas
MFMaría Ferris
María Ferris
CYCristina Veintimilla Yánez
Cristina Veintimilla Yánez
TGthe Gregorio Marañón Microbiology-ID COVID 19 Study Group
the Gregorio Marañón Microbiology-ID COVID 19 Study Group
The emergence of the Omicron variant of SARS-CoV-2 represented a challenge to the treatment of COVID-19 with monoclonal antibodies. Only Sotrovimab maintained partial activity, allowing it to be used in high-risk patients infected with the Omicron variant. However, the reports of resistance mutations to Sotrovimab call for efforts to better understand the intra-patient emergence of this resistance. A retrospective genomic analysis was conducted on respiratory samples from immunocompromised patients infected with SARS-CoV-2 who received Sotrovimab at our hospital between December 2021 and August 2022. The study involved 95 sequential specimens from 22 patients (1-12 samples/patient; 3-107 days post-infusion (Ct ≤ 32)). Resistance mutations (in P337, E340, K356, and R346) were detected in 68% of cases; the shortest time to detection of a resistance mutation was 5 days after Sotrovimab infusion. The dynamics of resistance acquisition were highly complex, with up to 11 distinct amino acid changes in specimens from the same patient. In two patients, the mutation distribution was compartmentalized in respiratory samples from different sources. This is the first study to examine the acquisition of resistance to Sotrovimab in the BA.5 lineage, enabling us to determine the lack of genomic or clinical differences between Sotrovimab resistance in BA.5 relative to BA.1/2. Across all Omicron lineages, the acquisition of resistance delayed SARS-CoV-2 clearance (40.67 vs 19.5 days). Close, real-time genomic surveillance of patients receiving Sotrovimab should be mandatory to facilitate early therapeutic interventions.